Nurix Therapeutics, Inc.: Form 10-Q for the period ended Aug 31, 2024
Filed with the SEC on Oct 11, 2024 and accepted by EDGAR at Oct 11, 2024, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-08-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-06-01 to 2024-08-31 | $12.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-12-01 to 2024-08-31 | $41.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2024-06-01 to 2024-08-31 | $55.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-12-01 to 2024-08-31 | $154.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-06-01 to 2024-08-31 | −$54.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-12-01 to 2024-08-31 | −$148.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-06-01 to 2024-08-31 | $82.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-12-01 to 2024-08-31 | $262.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-06-01 to 2024-08-31 | −$49.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-12-01 to 2024-08-31 | −$135.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-06-01 to 2024-08-31 | −$0.67 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-12-01 to 2024-08-31 | −$2.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-06-01 to 2024-08-31 | −$0.67 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-12-01 to 2024-08-31 | −$2.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-06-01 to 2024-08-31 | 72,779,381 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-12-01 to 2024-08-31 | 63,384,174 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-12-01 to 2024-08-31 | −$123.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-12-01 to 2024-08-31 | $7.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-08-31 | $99.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-08-31 | $456.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-08-31 | $513.6m | us-gaap:Assets |
| Current liabilities | At period end2024-08-31 | $86.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-08-31 | $136.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-08-31 | $376.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001549595-24-000131. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.